Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.
|
29273807 |
2018 |
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
Chronic Obstructive Airway Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency.
|
27878892 |
2017 |
Pulmonary Emphysema
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The G allele of rs2075803 and rs2075803 G/rs2258983 A(GA) haplotype in SIGLEC9 was associated with higher frequency of exacerbations and the extent of emphysema in COPD.
|
27878892 |
2017 |
COPD exacerbation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We examined whether SIGLEC9 polymorphisms affect the frequency of COPD exacerbation in 135 subjects within our study population, and also analysed the correlation between the genotypes and the severity of airflow obstruction and emphysema in 362 Japanese smokers including 244 COPD patients.
|
27878892 |
2017 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Targeting the tumor-restricted, glycosylation-dependent Siglec-9 axis may unleash this intratumoral T-cell subset, while confining T-cell activation to the tumor microenvironment.
|
30988027 |
2019 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we used affinity chromatography of tumor cell extracts to identify LGALS3BP as a novel sialic acid-dependent ligand for human Siglec-9 and for other immunomodulatory Siglecs, such as Siglec-5 and Siglec-10.
|
25320078 |
2014 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tumor microenvironment and disease progression.
|
27595232 |
2016 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Tumor-associated MUC1 binds to Siglec-9, which is expected to mediate tumor cell growth and negative immunomodulation.
|
24924635 |
2014 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Supporting this hypothesis, Siglec-9-expressing myelomonocytic cells found in human tumor samples were accompanied by a strong up-regulation of Siglec-9 ligands.
|
25225409 |
2014 |
Chronic Obstructive Airway Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, Siglec-9 was complementarily increased to induce a negative feedback loop to limit neutrophil activation in COPD, sSiglce-9 enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibiting ligands binding to Siglec-9.
|
28860481 |
2017 |
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, administration of recombinant human Siglec-9 Fc chimera protein significantly attenuated collagen-induced arthritis development in vivo and in vitro by reciprocal regulation of the differentiation of Th17 and Treg cells.
|
28273363 |
2017 |
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, Siglec-9 may serve as a potential diagnostic and therapeutic target for RA.
|
28273363 |
2017 |
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting Neutrophils in Severe Asthma via Siglec-9.
|
29306942 |
2018 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Targeting Siglec-7 and Siglec-9, or the sialic acid coated tumor cell surface is therefore being investigated as a novel therapeutic approach to enhance the NK cell response against cancer.
|
31143186 |
2019 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
In keeping with this, a human polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients, which suggests that Siglec-9 might be therapeutically targeted within the right time frame and stage of disease.
|
25225409 |
2014 |
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |
Guillain-Barre Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation.
|
29342882 |
2018 |
leukemia
|
0.010 |
Biomarker
|
disease |
LHGDN |
The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
|
15557178 |
2004 |
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia.
|
29306942 |
2018 |
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury.
|
24895121 |
2014 |
Complete atrioventricular block
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neutralization of Siglec-9 restored cytokine synthesis and degranulation of NK cells from CHB patients.
|
29899741 |
2018 |
Liver Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Secreted Ectodomain of SIGLEC-9 and MCP-1 Synergistically Improve Acute Liver Failure in Rats by Altering Macrophage Polarity.
|
28272428 |
2017 |
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury.
|
24895121 |
2014 |
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |